Ascletis Pharma Inc. is a biotechnology company focused on the research, development, manufacture, marketing, and sale of pharmaceutical products, primarily in Mainland China and internationally. The company offers several antiviral treatments, including Ganovo for hepatitis C, Pegasys for hepatitis B and C, and Ravidasvir, a pan-genotypic NS5A inhibitor for HCV. Its product pipeline features ASC22, a PD-L1 antibody fragment in Phase II trials for chronic hepatitis B, ASC40, a fatty acid synthase inhibitor for non-alcoholic steatohepatitis (NASH) also in Phase II readiness, and ASC41, an oral THR-ß agonist for NASH. Additionally, Ascletis is advancing therapies such as ASC09, a protease inhibitor that has completed Phase IIA trials for HIV, and ASC06, which has finished Phase I trials for liver cancer. The company is also exploring treatments in pre-clinical stages for hepatitis B and NASH. Founded in 2014 and headquartered in Hangzhou, China, Ascletis aims to create a sustainable business model through innovative drug development and commercialization strategies tailored to the growing Chinese pharmaceutical market.